Építés alatt – nem éles oldal
Belépés

NCT06984757Csak meghívásos

Mid-frontal Delta/Theta and Cognitive Control

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. máj. 22. · Több mint 12 hónapja nem frissült - kérdezd meg a helyszínt, nyitott-e még

Következő lépések

Rövid összefoglaló (regiszter, angolul)

Abstract Cognitive symptoms of Parkinson's disease (PD) include deficits in attention, working memory, and reasoning. These deficits affect up to 80% of PD patients and lead to mild cognitive impairment (PD-MCI) and dementia in PD (PDD). There is a critical need to better understand cognitive impairment in PD to develop new targeted treatments. The long-term goal is to define the mechanisms of PD-related cognitive impairment. PD involves diverse processes such as dopamine and acetylcholine dysfunction, synuclein aggregation, and genetic factors. During the past funding period, the investigators linked PD-related cognitive impairment to dysfunction in frontal midline delta (1-4 Hz) and theta (5-7 Hz) rhythms, which the work has established as a marker of cognitive control. However, it is unknown why PD patients have deficits in these low-frequency brain rhythms. The preliminary magnetic resonance imaging (MEG) and magnetoencephalography (MRI) implicate the anterior midcingulate cortex (aMCC) as a potential source of frontal midline delta/theta rhythms. In the next funding period, the objective is to determine the mechanisms and predictive power of delta/theta rhythms in PD, which will help to better understand the pathophysiology of PD-related cognitive impairment. Collaboration between the University of New Mexico (UNM) and University of Iowa (UI) that will bring together MEG, MRI, longitudinal EEG, and adaptive subthalamic (STN) deep-brain stimulation (DBS). The investigators will test the overall hypothesis that frontal midline delta/theta dysfunction contributes to cognitive impairments in PD. In Aim 1, the investigators will determine the structural basis for delta/theta rhythm deficits in PD. In Aim 2, the investigators will determine the predictive power of delta/theta rhythm deficits in PD. In Aim 3, the investigators will determine how tuned low-frequency STN DBS impacts cortical activity and cognition. The results will have relevance for basic-science knowledge of the fundamental pathophysiology of cognitive impairment in PD and related dementias. Because this proposal will study patients with PDD, the findings are directly relevant to Alzheimer's-related dementias (ADRD).

Állapot (regiszter)
Csak meghívásos
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
635 (tervezett)
Első benyújtás
2025. ápr. 16.
Kezdés
2017. szept. 25.
Elsődleges befejezés
2029. dec. 31.
Fő szponzor
Nandakumar Narayanan
Betegségek
Parkinson-kór
NCT-szám
NCT06984757

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó
  • Tervezett résztvevők: 635
  • 2017. szept. 25. és az elsődleges befejezés (2029. dec. 31.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Patients with dementia with Lewy Bodies and Alzheimer's disease, drug-induced parkinsonism, Parkinson's-plus, on investigational drugs, with hearing loss will be excluded, or with color-blindness will be excluded. Subjects with a history of neuropsychiatric disorders, like Schizophrenia or Depression will be also be excluded.

Más betegség

  • For the TMS sub-study, PD patients with DBS leads will be excluded and any subject with a seizure disorder will also be excluded. For the HD-tACS sub-study, PD patients with DBS leads will be excluded and any subject with a seizure disorder will also be excluded.
  • Control Group: patients with Alzheimer's Disease (AD) and dementia with Lewy Bodies (DLB) A group of patients with AD and DLB will be recruited for the cognitive tasks to compare data with PD. Since AD is non-dopamine deficiency disease so they can serve as another control group for the study.
  • with any neurological disorders, including epilepsy
    • Control Group: patients with mTBI A group of patients with mTBI will be recruited for the cognitive tasks to compare data with PD.
  • with any neurological disorders, including epilepsy
    • Control Group: Older Subjects with Mood Disorders A group of older individuals with Mood Disorders will be recruited to perform cognitive tasks to compare data with both PD with Mood Disorders and PD without Mood Disorders.
  • Exclusion criteria: 1) any neurological disorders, including epilepsy
    • Control subjects' mothers

Életkor

  • Control Group: Older Normal Subjects A group of older healthy individuals will be matched with subjects with Parkinson's disease in terms of age, sex, and years of education. We will also recruit a small group of older healthy individuals specifically to pilot new behavioral tasks.
  • with any neurological disorders, including epilepsy
    • Control group: Healthy young and middle-aged adults
  • A group of healthy young and middle-aged adults without Parkinson's disease or other neurological issues.
  • 1) age range = 18-60 years old

Egyéb

  • Control Group: patients with 16pDel Autism A group of patients with 16pDel Autism will be recruited for the cognitive tasks to compare data with PD.
  • Control Group: patients with Brain Lesions A group of patients with Brain Lesions will be recruited for the cognitive tasks to compare data with PD.
  • The group of mothers of the healthy young adult control subjects.

Kiket keres a vizsgálat

  • GROUP 1: Parkinson's disease without cognitive impairment
  • Parkinson's disease, with MOCA > 26
  • under stable PD medication
  • able to walk independently, make their own decisions
  • age range = 18 - 89 years old
    • GROUP 2: Parkinson's disease with mild cognitive impairment
  • Parkinson's disease, with MOCA 23-26
  • under stable PD medication
  • able to walk independently, make their own decisions
  • age range = 18 - 89 years old
    • GROUP 3: Parkinson's disease with dementia
  • Parkinson's disease, with MOCA < 23
  • under stable PD medication
  • Make their own decisions
  • age range = 18 - 89 years old
    • GROUP 4: Parkinson's disease with STN-DBS 1) Parkinson's disease with functioning bilateral STN-DBS electrodes 2) under stable PD medication 3) able to walk independently, make their own decisions 4) age range = 18 - 89 years old 5) THIS GROUP WILL NOT UNDERGO TMS
    • GROUP 5: Parkinson's disease without DBS and with no seizure history for EEG-TMS study
  • Parkinson's disease with MOCA 23-30
  • under stable PD medication
  • able to walk independently, make their own decisions
  • age range = 18 - 89 years old
    • GROUP 6: Essential tremor with VIM-DBS
  • Essential tremor with functioning bilateral VIM-DBS electrodes 2) able to walk independently, make their own decisions 3) age range = 18 - 89 years old 4) THIS GROUP WILL NOT UNDERGO TMS
    • GROUP 7: Parkinson's disease without DBS and with no seizure history for EEG-HD-tACS study 1) Parkinson's disease with MOCA 23-30 2) under stable PD medication 3) able to walk independently, make their own decisions 4) age range = 18 - 89 years old
  • age range = 18 - 89 years old (will have to match with the age of subjects with Parkinson's Disease)
  • age range = 18 - 89 years old (will have to match with the age of subjects with Parkinson's Disease)
  • age range = 18 - 89 years old (will have to match with the age of subjects with Parkinson's Disease)
  • age range = 18 - 89 years old (will have to match with the age of subjects with Parkinson's Disease)
  • age range = 35 - 99 years old (most of this group will have to match with the age of subjects with Parkinson's Disease. One subset from this group (N = 40) will be independent from the demographics of the subjects with Parkinson's Disease, so they can have a wider age range).
  • age range = 18 - 89 years old (will have to match with the age of subjects with Parkinson's Disease)

A regiszterben nem jelölt feltételek

  • We will study individuals with idiopathic mild-moderate Parkinson's Disease. Diagnosis will be confirmed by Dr. Narayanan - a neurologist.

Életkor a regiszterben: 18 év – 99 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
University of IowaIowa CityEgyesült ÁllamokIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.